Registration is open for September 9th Event Registration is Limited to the First 200 Registrants so Register Early
The Power of Outsourcing in Early through Preclinical Drug Development
September, 9th 2010
Hyatt Regency in La Jolla
Mark your calendar and plan to join us for a one day Symposium featuring 9 senior level pharmaceutical and biotechnology industry speakers in a keynote address, case study presentations and discussions covering hot topics and end-to-end solutions across the drug-development spectrum. The presentations will explore a number of issues related to “Early through Preclinical Drug Development” and features internationally recognized experts in drug discovery and development discussing topics including:
Keynote Topic: The objective of this presentation is to provide the biotech companies the most effective ways of outsourcing pre-clinical testing. These will include identifying the criteria for choosing the appropriate contract lab based on its history, capabilities, expertise, and finally making a choice between science and quality of the product versus cost.
Panel Topics:
Medicinal Chemistry: IP generation, hit validation, lead optimization and solving tough synthetic problems
In Vitro Approaches for Organ Specific Toxicity Screening: A new in vitro approach designed to determine if a drug will cause adverse effects in liver, heart, or kidney. By incorporating a two cell model, organ specific toxicity endpoints, and markers of general cell health that it is possible to identify a drugs potential to cause liver, heart, or kidney toxicity
Challenges Associated with “Metabolomics”: The comprehensive, integrated analytical and data handling platform that provide a chemo-centric global metabolism analyses of biological systems. Presenting a specific case study describing the impact of this platform in a Drug Mechanism of Action Study
“Biologics,” or Large Molecules: Showcasing many significant ways in which the development process of a large molecule differs from that of traditional small molecules, including immune response, dose solution preparatory considerations, species-specific pharmacologic factors, and delivery methods
Chemistry, Manufacturing and Control (CMC): Formulation and analytical development topics along with early phase cGMP clinical supply manufacturing.The presentation will provide participants with the fundamentals needed to successfully implement an early stage CMC development process
Phase I Clinical Pharmacology and Early Clinical Research Studies: Cardiac safety, PK/PD, drug interaction and methodology studies. Incorporating pharmacogenetics and biomarkers into exploratory and proof of concept studies
Date: Thursday, September 9th
Agenda: 4:00 p.m. - 5:00 p.m.Registration, Networking & Visiting Exhibit Hall: Complimentary cocktails and horsd'oeuvres will be served
5:00 p.m. - 8:30 p.m.: Panel Presentation
Keynote Speaker & Moderator:
Ali Faqi, Ph.D., DVM, DABT, MPI
Panel of Speakers:
Grace M. Furman, Ph.D., DABT CEO/President, Paracelsus, Inc.
Sylvie K. Sakata, PhD Senior Director Pfizer Inc. La Jolla and St Louis Lead External Research Solutions RCoE
David C. Zimmermann, CEO - Kalexsyn Inc.
James McKim, Ph.D., DABT - CSO, CeeTox Inc
John Ryals, Ph.D. - CEO, Metabolon
Dean Knuth - CEO, Jasper Clinic
David McGee, Ph.D., DABT – MPI Research
David Barnes, PhD - CSO, Velesco Pharmaceutical
8:30 p.m. -9:00 p.m. Q&A
9:00 p.m. Adjourn
Place: Hyatt Regency in La Jolla
Sponsorship levels: Diamond ($1,000.00); Platinum ($400.00), Gold ($200.00), and Silver ($100.00) To become a sponsor please email us at info@ialsn.org
Biocom
IALSN is a Proud Member of Biocom
Welcome to IALSN's Website. You can read more about IALSN here.If you are interested in joining our growing organization and/or have any comments or questions, please contact us.
Mailing List
Complete and submit the form below to sign up for the IALSN mailing list and receive meeting announcements and newsletters.
Although the data and information published in the Iranian-American Life Science Network, IALSN, have been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. IALSN provides this information on an "as is" basis. All warranties of any kind, express or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses and non-infringement of proprietary rights are disclaimed. Changes may be periodically made to the information herein; these changes may or may not be incorporated in any new version of the publication. If you have obtained information from any of the IALSN web pages from a source other than the IALSN pages, be aware that electronic data can be altered subsequent to original distribution. Data can also quickly become out of date. If you find any errors or omissions, we encourage you to report them to us via e-mail.
